In conclusion, our data demonstrate that NSCLC BM patients exhibit mainly a skewed systemic CD4+ T cell phenotype compared to healthy individuals, defined by the TH17/IL-17 axis. The gene discussed is IL17A; the disease is non-small cell lung carcinoma.